- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Weekly Round-Up: Cronos Exploring Sale Options
Recent reports indicate that cannabis operator Cronos Group is exploring a sale of the company, potentially to Curaleaf Holdings.
A report released this week has caused a frenzy of speculation about the possibility of a major cannabis deal.
Meanwhile, new data shows Canadian cannabis operators owe nearly C$4 million to the federal government in regulatory fees.
Keep reading to find out more cannabis highlights from the past five days.
Speculation swirls about major cannabis deal
According to a Reuters report published on Thursday (July 6), Cronos Group (NASDAQ:CRON,TSX:CRON) is in early talks regarding a sale of the company, potentially to Curaleaf Holdings (CSE:CURA,OTCQX:CURLF).
Unnamed sources familiar with the matter told the news outlet that Cronos has recently received "unsolicited indications of interest from third parties," and the company has confirmed this news.
"Cronos is in the initial stages of reviewing these indications of interest, and there can be no assurance that any agreement or transaction will result therefrom," the company said.
Cronos has financial backing from tobacco giant Altria (NYSE:MO).
Curaleaf Holdings issued a statement in response, saying it will not comment on market speculation.
"The Company does not intend to make further comment unless required by law," the firm said in its statement.
Operator fees in Canada grow for fourth year in a row
A report from MJBizDaily notes that unpaid regulatory fees from Canadian cannabis operators have reached almost C$4 million, a 200 percent increase from a year ago, as companies struggle to make ends meet.
These fees have been increasing since 2019 and amount to 2.3 percent of a company's gross revenue for the year.
The Canadian cannabis industry has struggled mightily since the promise of a never-ending growth cycle dissipated into an expensive reality. Stakeholders have raised their voices to argue against what they believe is an unjust landscape when it comes to operating fees, but have seen little success so far.
These financial struggles have led operators to significantly downsize their businesses and ambitions outside of Canada.
Cannabis company news
- Clever Leaves Holdings (NASDAQ:CLVR)closed a sale for international assets, including its EU-GMP-certified cannabis processing facility in Portugal. The purchase by an affiliate of Curaleaf Holdings totaled 2.5 million euros.
- Entourage Health (TSXV:ENTG,OTCQX:ETRGF)completed a shipment of 100 kilograms of bulk medical cannabis to the Australian market.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.